Infliximab use in ulcerative colitis flare with Clostridium difficile infection: A report of two cases and literature review.
Open Access
- 1 January 2017
- journal article
- review article
- Published by Kare Publishing in Northern Clinics of Istanbul
- Vol. 5 (3), 256-260
- https://doi.org/10.14744/nci.2017.79446
Abstract
Clostridium difficile infection (CDI) is a major cause of morbidity and mortality in patients with inflammatory bowel disease (IBD), especially in ulcerative colitis (UC). The incidence and severity of CDI in IBD has shown an increasing trend in the last two decades. Patients with IBD are predisposed to CDI secondary to the recurrent use of antibiotics, corticosteroids, and immunosuppressants and secondary to dysbiosis. It is clinically challenging to distinguish the symptoms of CDI from an IBD flare. The worsening of IBD symptoms demands escalation of steroids or initiation of biologics. However, the management of CDI in IBD, not responding to antibiotics, is not well described beyond a few case reports. We report two cases of CDI with active UC flare. The patients did not respond to antibiotics or intravenous corticosteroids but had rapid resolution of CDI symptoms after receiving infliximab infusion. The optimal dosing and infusion frequency of infliximab in management of CDI in UC/IBD remains to be established.Keywords
This publication has 27 references indexed in Scilit:
- The intestinal microbiota dysbiosis andClostridium difficileinfection: is there a relationship with inflammatory bowel disease?Therapeutic Advances in Gastroenterology, 2012
- Diagnostic Accuracy of Real-time Polymerase Chain Reaction in Detection of Clostridium difficile in the Stool Samples of Patients With Suspected Clostridium difficile Infection: A Meta-AnalysisClinical Infectious Diseases, 2011
- Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's diseaseScandinavian Journal of Gastroenterology, 2010
- Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)Infection Control & Hospital Epidemiology, 2010
- Combination Immunomodulator and Antibiotic Treatment in Patients With Inflammatory Bowel Disease and Clostridium difficile InfectionClinical Gastroenterology and Hepatology, 2009
- Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infectionsAlimentary Pharmacology & Therapeutics, 2009
- Clinical Outcomes of Patients with Ulcerative Colitis and Co-existing Clostridium difficile InfectionDigestive Diseases and Sciences, 2009
- Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel diseaseGut, 2007
- Intravenous Immunoglobulin for the Treatment of Severe, Refractory, and Recurrent Clostridium difficile DiarrheaDiseases of the Colon & Rectum, 2006
- Antibiotic-Associated Pseudomembranous Colitis Due to Toxin-Producing ClostridiaNew England Journal of Medicine, 1978